Novogenia Expands U.S. Market with Comprehensive MGT Plus Methylation Test

Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and reinforces their commitment to innovative genetic analysis and longevity research.

Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in the function and processing of biological molecules, including vitamins and neurotransmitters. While standard tests typically analyze only a limited number of genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways. These include energy and nutrient metabolism, stress and neurotransmitter regulation, as well as vascular, immune, and cellular health.

The expanded scope of MGT Plus offers more precise insights into key biochemical processes, enabling a deeper understanding of genetic factors involved in methylation-related metabolic pathways. Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of this advancement: 'With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies.'

The global direct-to-consumer testing market is experiencing robust growth, with the market size reaching approximately $4.7 billion in 2025 and projected to grow to over $16.0 billion by 2033. The genetic testing sector is particularly dynamic, representing over 40% of the market, and North America leads with about 50% of global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information and preventive care.

Novogenia's collaboration with 10X Health underscores its dedication to making scientific innovations accessible internationally. By expanding its product portfolio and strengthening its presence in the U.S. market, Novogenia is well-positioned to capitalize on the growing demand for personalized health solutions. For more information about Novogenia and its offerings, visit Novogenia's website.